Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0KPDCG
ADC Name
Anti-MSLN-45 ADC
Synonyms
Anti-MSLN 45 ADC; meso-45
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Gastric cancer [ICD11:2B72]
Investigative
Drug-to-Antibody Ratio
3
Antibody Name
Anti-MSLN mAb
  Antibody Info 
Antigen Name
Mesothelin (MSLN)
  Antigen Info 
Payload Name
Tetrahydroisoquinoline-based PBD dimer 17
  Payload Info 
Therapeutic Target
Human Deoxyribonucleic acid (hDNA)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
Conjugate Type
Random heterogeneous lysine conjugation
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.04
nM
NCI-N87 cells
Gastric tubular adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.04 nM Positive MSLN expression (MSLN+++/++)
Method Description
Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model Gastric tubular adenocarcinoma NCI-N87 cells CVCL_1603
References
Ref 1 Design, Synthesis, and Structure-Activity Relationships of Novel Tetrahydroisoquinolino Benzodiazepine Dimer Antitumor Agents and Their Application in Antibody-Drug Conjugates. J Med Chem. 2020 Nov 25;63(22):13913-13950. doi: 10.1021/acs.jmedchem.0c01385.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.